App-Quantinova.ai

The Chromosome 21 Kinase DYRK1A Controls Cell Cycle Exit and Survival During Lymphoid Development and Is a Novel Therapeutic Target In Acute Lymphoblastic Leukemia

Benjamin J Thompson - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cytarabine liposomal

Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome

Kathryn G. Roberts - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (Ph-like or BCR-ABL1-Like) Signature For Therapeutic Targeting and Clinical Intervention

Richard C. Harvey - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

L-Tyrosine

Mir~17-92 Identifies BCL2 As a Therapeutic Target In BCR-ABL Positive B-Lineage Acute Lymphoblastic Leukemia

Matthias Eder - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Imatinib

The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL

Behzad Kharabi Masouleh - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute lymphoblastic leukemia

Tamoxifen

Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Childrens Oncology Group (COG) AALL0331

Kelly W. Maloney - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Significant Improvement Of Outcome In Adolescents and Young adults (AYAs) Aged 15-35 Years With Acute Lymphoblastic Leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL)

Nicola Gokbuget - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

PEG-asparaginase

Stathmin 1 Is Involved In The Highly Proliferative Phenotype Of High-Risk Myelodysplastic Syndromes and Acute Leukemia Cells

Joao Agostinho Machado-Neto - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

A Mechanistic Role For Mir-126, a Hematopoietic Stem Cell Microrna, In Acute Leukemias

Alice Giustacchini - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Tetracycline

ALT-1188: A New CXCR4 Antagonist In Development For Mobilization Of HSPCs

Michael P. Rettig - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Plerixafor

Cytomegalovirus Reactivation After Allogeneic Stem Cell Transplantation Is Associated With a Reduced Risk Of Relapse In Patients With Acute Myeloid Leukemia: The Japan Society For Hematopoietic Cell Transplantation (JSHCT) Transplantation-Related Complication Working Group

Katsuto Takenaka - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Allopurinol

CTLA-4 Polymorphisms: Influence on Transplant-Related Mortality and Survival in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Bernd Gruhn - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclosporine A

Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes

Anita J Kumar - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Lewis B. Silverman - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Erwinase

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Renato Bassan - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cytarabine liposomal

Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia

Chengcheng Liu - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allmercap

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Shannon L Maude - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Stephan A. Grupp - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

CTL019

Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells Are Also Resistant to ABL Inhibitors, Which Can be Overcome By Targeting the PI3K/AKT/ mTOR Pathway

Jessica T Leonard - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Venetoclax

Lysosomal Cell Death and Apoptosis Crosstalk - Synergistic Role in Bcl-2 Inhibitor (ABT-263) Mediated Cell Death in B-Cell Precursor Acute Lymphoblastic Leukemia

Stefanie Enzenmuller - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Filters

2187 Abstracts